2015 Drug Recalls: While FDA Drove Pharmacies, Quality Systems Drove Manufacturers
This article was originally published in The Gold Sheet
Executive Summary
Huge recall numbers last year reflected FDA's continued enforcement of sterility assurance at compounding pharmacies, while generic and brand manufacturers dealt with particulate contamination and various out-of-specification issues.
You may also be interested in...
FDA Warning Letter Slams Another Asian API Firm On Data Integrity
Data integrity warning letter to Chinese API maker reflects continuing focus of FDA enforcement efforts on the pharmaceutical industry's Asian supply chain.
Contamination Issues Drove Drug Recalls to Record Levels in 2011
How contamination, sterility assurance, OOS and other issues caused drug recalls to spike again last year. What happened at Aidapak, H&P, Ben Venue, Hospira, Teva and other manufacturers to set a new record.
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.